ONCAlert | 2018 ASCO Annual Meeting
Videos  >  

Dr. Michael Birrer on Bevacizumab in Ovarian Cancers

Michael Birrer, MD, PhD
Published Online:1:27 PM, Mon December 28, 2015

Michael Birrer, MD, PhD, director, Medical Gynecologic Oncology Director, Gynecologic Oncology Research Program, Massachusetts General Hospital Cancer Center, professor of Medicine, Harvard Medical School, discusses several international phase III trials showing bevacizumab significantly prolonging progression free survival in patients with ovarian cancer.

Birrer says four phase III studies examined bevacizumab in four different types of ovarian cancers, each of which responded well to the treatment. He adds that the next step for bevacizumab, an antiangiogenic agent, is to find out which patients respond to the treatment the best and which do not respond much, if at all. 
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.